Shares of Roquefort Therapeutics plc (LON:ROQ – Get Free Report) fell 3.3% on Tuesday . The company traded as low as GBX 4.10 ($0.05) and last traded at GBX 4.35 ($0.05). 761,441 shares changed hands during mid-day trading, an increase of 27% from the average session volume of 600,833 shares. The stock had previously closed at GBX 4.50 ($0.06).
Roquefort Therapeutics Stock Performance
The company has a market cap of £4.94 million, a price-to-earnings ratio of -382.40 and a beta of 0.05. The firm’s 50 day simple moving average is GBX 4.28 and its 200-day simple moving average is GBX 4.19. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79.
Roquefort Therapeutics Company Profile
Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.
Featured Articles
- Five stocks we like better than Roquefort Therapeutics
- What is a support level?
- Micron Stock Under $100: Seize the AI-Driven Upside
- What Are Growth Stocks and Investing in Them
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- What Do S&P 500 Stocks Tell Investors About the Market?
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
